Komori
OncoTherapy Science (4564) · FactRestatedLatest General Meetings of Shareholders (2026-06-01): "Reframed"

Change in Audit Firm

First written in FY2021-Q1. 7 of 10 entries say "Restated". Latest entry: 2026-06-01.

10entries
7years
2from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2021-Q1 – FY2026-H12020: 220202021: 220212022: 220222023: 120232024: 020242025: 120252026: 22026
Same theme, other companies
Change of Accounting AuditorA theme 778 companies write about · 1 as a headwind · 37 as a tailwind
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 200 companies compared. The sentences above are computed from all 200.Comparing 200 of the theme's 778 threads.
Full recordFilings, disclosures and news, newest first
  2. FY2026-H1RestatedAnnual report

    「Pursuant to Article 193-2, Paragraph 1 of the Financial Instruments and Exchange Act, the Company has undergone an interim review by Yamato Audit Corporation of the interim consolidated financial statements for the interim consolidated accounting period (from 1 April 2025 to 30 September 2025).」

    The Company continues to undergo interim reviews by Yamato Audit Corporation.
  3. FY2023-Q3RestatedAnnual report

    「Pursuant to Article 193-2, Paragraph 1 of the Financial Instruments and Exchange Act, the Company has undergone a quarterly review by Yamato Audit Corporation of the quarterly consolidated financial statements for the third quarter of the consolidated fiscal year (from 1 October 2022 to 31 December 2022) and the cumulative third quarter period (from 1 April 2022 to 31 December 2022).」

    The Company also underwent a quarterly review by Yamato Audit Corporation in the third quarter of the 22nd fiscal year.
  4. FY2023-Q1RestatedAnnual report

    「Pursuant to Article 193-2, Paragraph 1 of the Financial Instruments and Exchange Act, the Company has undergone a quarterly review by Yamato Audit Corporation of the quarterly consolidated financial statements for the first quarter of the consolidated fiscal year (from 1 April 2022 to 30 June 2022) and the cumulative first quarter period (from 1 April 2022 to 30 June 2022).」

    The Company also underwent a quarterly review by Yamato Audit Corporation in the first quarter of the 22nd fiscal year.
  5. FY2022-Q3RestatedAnnual report

    「Pursuant to Article 193-2, Paragraph 1 of the Financial Instruments and Exchange Act, the Company has undergone a quarterly review by Yamato Audit Corporation of the quarterly consolidated financial statements for the third quarter of the consolidated fiscal year (from 1 October 2021 to 31 December 2021) and the cumulative third quarter period (from 1 April 2021 to 31 December 2021).」

    The Company also underwent a quarterly review by Yamato Audit Corporation in the third quarter of the 21st fiscal year.
  6. FY2022-Q1RestatedAnnual report

    「Pursuant to Article 193-2, Paragraph 1 of the Financial Instruments and Exchange Act, the Company has undergone a quarterly review by Yamato Audit Corporation of the quarterly consolidated financial statements for the first quarter of the consolidated fiscal year (from 1 April 2021 to 30 June 2021) and the cumulative first quarter period (from 1 April 2021 to 30 June 2021).」

    The Company also underwent a quarterly review by Yamato Audit Corporation in the first quarter of the 21st fiscal year.
  7. FY2021-Q3RestatedAnnual report

    「19th consolidated fiscal year　　　　　　　　Deloitte Touche Tohmatsu LLC Third quarter of the 20th consolidated fiscal year and cumulative third quarter period　　　Yamato Audit Corporation」

    The Company reconfirmed that Yamato Audit Corporation remained the audit firm in the third quarter of the 20th fiscal year.
  8. FY2021-Q2RestatedAnnual report

    「Second quarter of the 20th consolidated fiscal year and cumulative second quarter period　　　Yamato Audit Corporation」

    The Company reconfirmed that Yamato Audit Corporation remained the audit firm in the second quarter of the 20th fiscal year.
  9. FY2021-Q1First statedAnnual report

    「The Company's audit firm has changed as follows. 19th consolidated fiscal year　　　　　　　　Deloitte Touche Tohmatsu LLC First quarter of the 20th consolidated fiscal year and cumulative first quarter period　　　Yamato Audit Corporation」

    From the first quarter of the 20th fiscal year, the audit firm changed from Deloitte Touche Tohmatsu LLC to Yamato Audit Corporation.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for OncoTherapy Science yet. It last moved in the General Meetings of Shareholders of 2026-06-01: "Reframed".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Change in Audit Firm | OncoTherapy Science,Inc. (4564) | Komori